Evidence network for deaths_(OS)

1ATTRACTION-2 (Kang), 20172KEYNOTE-061 (PDL1 CPS>1), 2018 KEYNOTE-061 (all population), 20182KEYNOTE-062 (P vs C ; CPS>10), 2020 KEYNOTE-062 (P vs C ; CPS>1), 20201JAVELIN Gastric 300, 20182JAVELIN Gastric 100, 2020 JAVELIN Gastric 100 (PDL1>1%), 20202CheckMate 649 (PDL1 CPS>5), 2021 CheckMate 649, 20211CA184-162, 20172KEYNOTE-062 (PC vs C ; CPS>1), 2020 KEYNOTE-062 (PC vs C ; CPS>10), 2020placebopaclitaxelStandard of Care (SoC)irinotecanplacebo plus SoCnivolumab alonepembrolizumab aloneavelumab alonenivolumab plus SoCIpilimumab (10 mg/kg)pembrolizumab plus SoCdirect evidencenetwork meta-analysis
T vs. C placebopaclitaxelStandard of Care (SoC)irinotecanplacebo plus SoCnivolumab alonepembrolizumab aloneavelumab alonenivolumab plus SoCIpilimumab (10 mg/kg)pembrolizumab plus SoC
placebo---NANANANANANANANANANA
paclitaxelNA---NANANANANANANANANA
Standard of Care (SoC)NANA---NANANANANANANANA
irinotecanNANANA---NANANANANANANA
placebo plus SoCNANANANA---NANANANANANA
nivolumab aloneNANANANANA---NANANANANA
pembrolizumab aloneNANANANANANA---NANANANA
avelumab aloneNANANANANANANA---NANANA
nivolumab plus SoCNANANANANANANANA---NANA
Ipilimumab (10 mg/kg)NANANANANANANANANA---NA
pembrolizumab plus SoCNANANANANANANANANANA---

pathologies: 273,122,271,262,260,219,184,272,123,187,185,186,304 - treatments: 873 result logic